Bank of America
ADCT icon

Bank of America’s ADC Therapeutics ADCT Stock Holding History

Bank of America’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.97M Buy
1,325,017
+26,433
+2% +$104K ﹤0.01% 3479
2025
Q4 		$4.58M Sell
1,298,584
-62,706
-5% -$254K ﹤0.01% 3463
2025
Q3 		$5.45M Sell
1,361,290
-837,769
-38% -$2.64M ﹤0.01% 3914
2025
Q2 		$5.89M Buy
2,199,059
+397,905
+22% +$837K ﹤0.01% 3724
2025
Q1 		$2.54M Buy
1,801,154
+509,910
+39% +$866K ﹤0.01% 4465
2024
Q4 		$2.57M Sell
1,291,244
-1,206,696
-48% -$3.16M ﹤0.01% 4228
2024
Q3 		$7.87M Buy
2,497,940
+1,281,522
+105% +$4.04M ﹤0.01% 3296
2024
Q2 		$3.84M Buy
1,216,418
+22,571
+2% +$89.7K ﹤0.01% 3861
2024
Q1 		$5.36M Sell
1,193,847
-331,894
-22% -$1.22M ﹤0.01% 3552
2023
Q4 		$2.53M Sell
1,525,741
-8,190
-0.5% -$7.56K ﹤0.01% 4171
2023
Q3 		$1.38M Sell
1,533,931
-132,781
-8% -$177K ﹤0.01% 4578
2023
Q2 		$3.58M Buy
1,666,712
+21,904
+1% +$49.2K ﹤0.01% 3701
2023
Q1 		$3.21M Buy
1,644,808
+40,182
+3% +$148K ﹤0.01% 3949
2022
Q4 		$6.16M Buy
1,604,626
+1,597,765
+23,288% +$6.39M ﹤0.01% 3202
2022
Q3 		$33K Buy
6,861
+519
+8% +$3.76K ﹤0.01% 6826
2022
Q2 		$50K Sell
6,342
-1,267
-17% -$12K ﹤0.01% 6824
2022
Q1 		$112K Sell
7,609
-93,268
-92% -$1.48M ﹤0.01% 6795
2021
Q4 		$2.04M Buy
100,877
+92,621
+1,122% +$2.23M ﹤0.01% 4530
2021
Q3 		$225K Sell
8,256
-1,630
-16% -$41.7K ﹤0.01% 6219
2021
Q2 		$240K Sell
9,886
-3,993
-29% -$92.7K ﹤0.01% 5974
2021
Q1 		$339K Buy
13,879
+11,462
+474% +$332K ﹤0.01% 5663
2020
Q4 		$77K Sell
2,417
-1,500
-38% -$49.2K ﹤0.01% 6112
2020
Q3 		$129K Buy
3,917
+407
+12% +$17.6K ﹤0.01% 5543
2020
Q2 		$164K Buy
+3,510
New +$133K ﹤0.01% 5372

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America's ADCT Position: Q1 2026 in Review

Bank of America increased its ADC Therapeutics (ADCT) stake by 2% in Q1 2026, buying an estimated $104K and bringing the position to 1,325,017 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3479.

Bank of America first reported a position in ADCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $7.87M in Q3 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Bank of America held 1,325,017 shares of ADC Therapeutics worth $4.97M as of Q1 2026.
  • Bank of America bought 26,433 ADC Therapeutics shares in Q1 2026, an estimated $104K.
  • ADC Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3479 holding.
  • Bank of America first reported a position in ADC Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Bank of America's ADC Therapeutics position peaked at $7.87M in Q3 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.